The drug proves to prevent hospitalization if taken when early | Dr. Vladimir Zelenko (Zelenko Protocol)
The drug proves to prevent hospitalization if taken when early symptoms of COVID-19 arise. The drug is cost-effective at 60 cents per tablet with COVID-19 treatment consisting of 11 tablets taken over five days. The FDA considers HCQ to be a safer drug than Tylenol.
10. March 23, 2020 — The Director of BARDA, (Biological Advanced Research Development Authority) Rick Bright Ph.D., is instructed by his superiors to work with the FDA to establish an Investigational New Drug (IND) authorization for HCQ. The next day, the Director of Drug Evaluation and Research at the Food and Drug Administration (FDA), Dr. Janet Woodcock MD, contacts Rick Bright at BARDA.
11. March 24, 2020 — Dr. Woodcock wrongly advises Bright that HCQ is a dangerous drug requiring a EUA (Emergency Use Authorization). Its use should be limited to hospitalized patients. Bright and Dr. Woodcock promote this course of action,
despite the early clinical data showing HCQ was the most effective in outpatients if given early during the initial infection, effectively eliminating hospitalization. The FDA issues a EUA for HCQ — for hospital use only.
· In a legal document, Rick Bright makes a blatant admission of insubordination to multiple layers of leadership, including the White House, HHS Secretary Azar, and Dr. Robert Kadlec, MD, the Assistant HHS Secretary for Preparedness and Readiness.
· Bright states the following in his Whistleblower Complaint: “…instead of a Nationwide Expanded Access IND protocol. Implementing the EUA was a compromise position, to rein in HHS leadership’s initial campaign to make the drugs available to the public outside of a hospital setting”
Question: When is it ever acceptable to “compromise” public health during a rampaging pandemic?
12. April 4, 2020 — Dr. Anthony Fauci MD, the member of the COVID-19 Task Force responsible for informing the President of the best course of action for pandemic control, appears to be unaware of the National Pandemic Plan. In a heated White House Situation Room meeting, Dr. Fauci refused to consider the use of HCQ for COVID-19 treatment. He dismisses the ever-accumulating HCQ efficacy reports from China, South Korea, and France as simply “anecdotal.”
13. April 22, 2020 — Rick Bright is fired as BARDA Director for his insubordination. Before his dismissal, he falsely informed the press that HCQ is a dangerous drug.
14. Dr. Anthony Fauci, Director of NIAID, who is not a virologist, disregards the National Pandemic Plan, which included outreach programs with physicians using HCQ for outpatient treatment and prevention to bring the COVID-19 pandemic under control.
Dr. Fauci brushes off the accumulating evidence and diverts millions of federal funds into a program to test and manufacture an experimental drug named Remdesivir.
Remdesivir must be administered via IV and can only in the hospital. Instead of early community treatment, as prescribed in the original pandemic plan. Dr. Fauci changes the plan to promote “Societal Lockdowns” and push the development of highly experimental mRNA vaccines by multinational pharmaceutical corporations.
NOTE: Members of Fauci’s Covid-19 treatment panel have ties to Gilead Sciences, Inc. (Foster City, CA), the company that holds the patent for Remdesivir.
15. May 16, 2020 — In Phase 1 clinical trials conducted by Gilead Sciences in cooperation with China and Japan, Remdesivir FAILED: “no statistically clinical effect, with severe adverse reactions.”
NOTE: On October 16, 2020, the WHO concludes that Remdesivir is an ineffective drug and does not recommend its use to treat COVID-19.
16. May 20, 2020 — Shortly after becoming Senior Medical Advisor to the FDA Commissioner, Dr. Woodcock recused herself over future decisions concerning vaccines, citing a conflict of interest.
17. June 15, 2020 — Dr. Fauci ignores the data that HCQ works if the drug is administered during the first five days of infection. Its EUA is revoked, despite the overwhelming evidence of its effectiveness.
